What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

ANAmmar NasirKhyber Teaching Hospital RBRayyan Mohammad Makki BakhshFoundation University Medical College AKAmal KhanSaskatchewan Health Authority

Discussion

Member takes

Implication

Systematic review and meta-analysis finds crizanlizumab ineffective for reducing vaso-occlusive crises in sickle cell disease, suggesting further trials needed.

Key Points

Crizanlizumab did not significantly reduce vaso-occlusive crises compared to placebo, with a risk ratio of 0.97.
The analysis included 299 patients on crizanlizumab and 317 on placebo, highlighting a need for more comprehensive studies.
Randomized controlled trials and observational studies were assessed, following PRISMA guidelines for systematic reviews.
The findings indicate possible higher adverse events with crizanlizumab, warranting further investigation of its clinical utility.

Cite This Study

Nasir et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2de https://doi.org/10.1182/blood-2025-6498

View Full Paper

Ask AI

Bookmark

Implication

Systematic review and meta-analysis finds crizanlizumab ineffective for reducing vaso-occlusive crises in sickle cell disease, suggesting further trials needed.

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of crizanlizumab in sickle cell disease : A systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider